Skip to main content


  • Tuesday, Aug 26th
    1:30 PM - 1:35 PM ET
    6D-01 - Real-World Use and Survival Outcomes of Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer and Hormone Receptor-Positive/HER2-Negative Breast Cancer: Insights from the French Early Access Program
    Presenting Author: Aya Elhusseiny SHAABAN, PharmD – EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM), Paris Saclay University, Université Versailles Saint Quentin (UVSQ - EDSP)
    Co-Author: Hugo Jourdain, PhD – EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM)
    Co-Author: David Desplas – EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM)
    Co-Author: Mahmoud Zureik, PhD, MD – EPI-PHARE Scientific Interest Group in Epidemiology of Health Products from the French National Agency for the Safety of Medicines and Health Products and the French National Health Insurance, St Denis, France ; Paris Saclay University, Université Versailles Saint Quentin (UVSQ - EDSP)
    Co-Author: Nadia Haddy, PhD, MD – EPI-PHARE, French National Agency for Medicine and Health Product Safety (ANSM) and the French National Health Insurance Center (CNAM)
    Drug Utilization Research / Other